Shotaro Yamamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shotaro Yamamoto has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Kojiro Sato
Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Tochigi, Japan
2 shared publications - Takeo Sato
Division of Rheumatology and Clinical Immunology, Department of Medicine Jichi Medical University Shimotsuke Tochigi Japan
2 shared publications - Yasuo Nagafuchi
Division of Rheumatology and Clinical Immunology, Department of Medicine Jichi Medical University Shimotsuke Tochigi Japan
2 shared publications Katsuya Nagatani
Division of Rheumatology and Clinical Immunology, Department of Medicine Jichi Medical University Shimotsuke Tochigi Japan
1 shared publication- Katsuya Nagatani
Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University , Shimotsuke, Tochigi
1 shared publication
Latest Publications
- 19 September 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (9) , e70880
Herpes Zoster Incidence Differs Among Janus Kinase Inhibitors, While Permanent Discontinuation Rates Remain Comparable
- 19 September 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (9) , e70880
Herpes Zoster Incidence Differs Among Janus Kinase Inhibitors, While Permanent Discontinuation Rates Remain Comparable
- 5 May 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (5)
Higher hydroxychloroquine dose based on actual body weight is associated with lower SLE flare risks while maintaining tolerability
Objectives: The effects of HCQ dose based on actual body weight (ABW) on SLE remain unclear. We investigated the effects of HCQ dose based on ABW of patients with SLE. Methods: Patients were classified into ≥5 mg/kg ABW [high dose (HD)] and <5 mg/kg ABW [low dose (LD)] groups. Patient backgrounds were adjusted using inverse probability of treatment weighting method. The discontinuation rate owing to adverse events of overall cohort (group 1) was evaluated. Subgroups with a disease duration ≥1 year (group 2) and without additional immunosuppressive agents and biologics after HCQ initiation (group 3) were compared with evaluated flare rates, prednisolone dose and serological data. Results: Among 182 patients in group 1, 60 (33%) comprised the HD group. Five-year discontinuation rates were 18.9% and 13.6% in the HD and LD groups, respectively (P = 0.314). Three-year flare-free rates in HD group were higher than those in LD group: 75.0% (HD) vs 60.7% (LD) (P = 0.239) in group 2, and 79.2% (HD) vs 57.8% (LD) (P = 0.141) in group 3. In group 3, each 0.2 mg/kg increase in the HCQ dose reduced flares (hazard ratio 0.91; 95% CI 0.84–0.99). Conclusion: No clear differences in efficacy and safety were observed between the HD and LD groups; however, a higher HCQ dose was associated with a reduced flare risk. Our findings suggest that a lower HCQ dose may be associated with a higher flare risk in patients with SLE, highlighting the importance of HCQ dose based on ABW.
- 5 May 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (5)
Higher hydroxychloroquine dose based on actual body weight is associated with lower SLE flare risks while maintaining tolerability
Objectives: The effects of HCQ dose based on actual body weight (ABW) on SLE remain unclear. We investigated the effects of HCQ dose based on ABW of patients with SLE. Methods: Patients were classified into ≥5 mg/kg ABW [high dose (HD)] and <5 mg/kg ABW [low dose (LD)] groups. Patient backgrounds were adjusted using inverse probability of treatment weighting method. The discontinuation rate owing to adverse events of overall cohort (group 1) was evaluated. Subgroups with a disease duration ≥1 year (group 2) and without additional immunosuppressive agents and biologics after HCQ initiation (group 3) were compared with evaluated flare rates, prednisolone dose and serological data. Results: Among 182 patients in group 1, 60 (33%) comprised the HD group. Five-year discontinuation rates were 18.9% and 13.6% in the HD and LD groups, respectively (P = 0.314). Three-year flare-free rates in HD group were higher than those in LD group: 75.0% (HD) vs 60.7% (LD) (P = 0.239) in group 2, and 79.2% (HD) vs 57.8% (LD) (P = 0.141) in group 3. In group 3, each 0.2 mg/kg increase in the HCQ dose reduced flares (hazard ratio 0.91; 95% CI 0.84–0.99). Conclusion: No clear differences in efficacy and safety were observed between the HD and LD groups; however, a higher HCQ dose was associated with a reduced flare risk. Our findings suggest that a lower HCQ dose may be associated with a higher flare risk in patients with SLE, highlighting the importance of HCQ dose based on ABW.